Skip to content
    Frazier Healthcare Partners logo

    Frazier Healthcare Partners

    Seattle, Washington, United StatesFounded 1991
    www.frazierhealthcare.comLinkedIn
    HealthcareBiotech & Life Sciences

    Frazier Healthcare Partners is a healthcare-focused private equity and venture capital firm founded in 1991 and headquartered in Seattle, Washington. The firm specializes in growth buyout and venture investments exclusively in the healthcare sector, including healthcare services, life sciences, pharmaceuticals, and medical products.

    37% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Average disclosed round size is $63.5M (across 94 rounds with reported amounts).

    Find people at Frazier Healthcare Partners on Goldilocks AI

    Portfolio

    72

    Fund Size

    $2.3B

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    BM

    Ben Magnano

    Managing Partner

    NN

    Nader Naini

    Managing Partner

    BM

    Brian Morfitt

    General Partner

    CR

    Christina Reszka

    General Partner

    NE

    Nathan Every, MD

    General Partner

    PZ

    Philip Zaorski

    General Partner

    RL

    Ryan Lucero

    General Partner

    AC

    Andy Caine

    CoE - COO and Partner

    AD

    Anthony Draye

    CoE - Partner, Technology & Innovation

    BH

    Ben Hansen

    CoE - Partner, Finance & Operations

    BA

    Brad Alexander

    CoE - Partner, Finance & Operations

    CW

    Caitlin Walker

    CoE - Partner, Human Capital

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    100 investments
    CompanyRoundAmountDate
    VVimaSeries A$100MMar 2026
    Entasis logoEntasisSeries B$50MJan 2026
    Iolyx Therapeutics logoIolyx TherapeuticsSeries B$15MDec 2025
    Normunity logoNormunitySeries B$75MJan 2025
    HHillstarSeries A$67MJan 2025
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MNov 2024
    AAlentisSeries D$181.4MNov 2024
    Gritstone Oncology logoGritstone OncologySeries B$92.7MJan 2024
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MJan 2024
    MMbx Biosciences IncSeries B$115MNov 2022
    SSanreno TherapeuticsUnknown$40MNov 2021
    HilleVax logoHilleVaxUnknown$135MSep 2021
    Sonoma Biotherapeutics logoSonoma BiotherapeuticsSeries B$265MAug 2021
    Hummingbird Bioscience logoHummingbird BioscienceSeries C$125MMay 2021
    Amunix logoAmunixSeries B$117MMar 2021
    AAmunix PharmaceuticalsSeries B$117MMar 2021
    Seraxis logoSeraxisSeries C$40MFeb 2021
    AAmunix PharmaceuticalsSeries B$117MJan 2021
    Amunix logoAmunixSeries B$117MJan 2021
    MMbx Biosciences IncSeries A—Nov 2020
    DDascenaSeries B$50MMay 2020
    Amunix logoAmunixSeries A$73MMar 2020
    Tarsus Pharmaceuticals logoTarsus PharmaceuticalsSeries B$60MJan 2020
    DDascenaSeries B$50MJan 2020
    AArcutisSeries C$94.5MOct 2019
    Page 1 of 4

    Top Co-Investors

    Longitude Capital17 shared
    OrbiMed13 shared
    Frazier Life Sciences12 shared
    RA Capital Management11 shared
    Canaan Partners11 shared
    Pivotal Life Sciences10 shared
    Novo Capital10 shared
    Osage University Partners9 shared
    Adams Street Partners9 shared
    Venrock9 shared
    Omega Funds9 shared
    Vivo Capital9 shared
    Domain Associates9 shared
    Bessemer Venture Partners8 shared
    BlackRock Private Equity Partners8 shared
    Polaris Partners7 shared
    Amgen Ventures7 shared
    New Leaf Venture Partners7 shared
    Novo Holdings A/S7 shared
    Third Rock Ventures6 shared

    Last updated: 20 October 2026